MELISSA AMANN: Open Payments
NPI 1275886012 · SAINT LOUIS, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$222 in 12 payments from 11 companies in 2025. Trend: 2023 $792 · 2024 $667 · 2025 $222
Food & beverage: $222
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 2 | $46 |
| Sumitomo Pharma America, Inc. | 1 | $29 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $22 |
| PFIZER INC. | 1 | $19 |
| Averitas Pharma Inc. | 1 | $18 |
| Abbott Laboratories | 1 | $16 |
| Amgen Inc. | 1 | $15 |
| Verona Pharma, Inc. | 1 | $15 |
| GlaxoSmithKline, LLC. | 1 | $15 |
| Electromed, Inc. | 1 | $14 |
Products named: GEMTESA, FARXIGA, JARDIANCE, BREZTRI, PREVNAR 20, QUTENZA, FREESTYLE LIBRE 3, OTEZLA.
Industry payments across MO — which companies pay providers there.
